SWOG clinical trial number
SWOG-9242

Evaluation of Taxotere in Small Cell Lung Carcinoma, Phase II

Closed
Phase
Accrual
94%
Published
Abbreviated Title
Evaluation of Taxotere in Small Cell Lung Carcinoma, Phase II
Activated
05/01/1993
Closed
01/15/1997

Research committees

Lung Cancer

Publication Information Expand/Collapse

1999

Evaluation of docetaxel in previously untreated extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial.

PJ Hesketh;JJ Crowley;HA Burris;SK Williamson;SP Balcerzak;DM Peereboom;JW Goodwin;HM Gross;DF Moore;RB Livingston;DR Gandara Cancer Journal from Scientific American 5(4):237-241

1998

Docetaxel (taxotere) in extensive stage small cell lung cancer (SCLC): A phase II trial of the Southwest Oncology Group (SWOG).

HA Burris;JJ Crowley;SK Williamson;DR Gandara;RB Livingston Proc of the American Society of Clinical Oncology 17:451a(#1737)

Other Clinical Trials

SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open